Table 5.6a

Immunosuppression Use for Induction, 1996 to 2005

Recipients with Kidney Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 11,397 11,701 12,451 12,758 13,611 14,265 14,778 15,136 16,004 16,477
With Immunosuppression Info 11,158 11,608 12,335 12,486 13,252 14,120 14,600 14,934 15,731 15,820
Induction Drugs 2.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 15.3% 17.3% 12.2% 6.6% 3.2% 2.5% 1.9% 1.1% 1.8% 1.6%
OKT3 21.4% 17.7% 10.0% 3.9% 1.8% 0.8% 0.9% 0.4% 0.3% 0.4%
Thymoglobulin 0.0% 0.0% 0.2% 4.9% 10.1% 17.1% 25.8% 33.6% 36.6% 38.6%
Zenapax 0.2% 0.2% 13.0% 16.5% 13.1% 14.4% 12.9% 12.5% 11.3% 11.5%
Simulect 0.6% 0.1% 5.0% 17.2% 26.6% 25.3% 26.4% 21.6% 19.0% 16.4%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 3.6% 6.8% 8.8%
No Induction Drugs Recorded 61.5% 65.7% 61.1% 53.0% 47.7% 42.5% 35.2% 30.2% 28.0% 26.4%


Source: OPTN/SRTR Data as of May 1, 2006.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.